Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KNX100 for agitation associated with dementia
ACTRN12624000747527Phase 2Recruiting
- Sponsor
- Kinoxis Therapeutics
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Dementia comparing KNX100 with Placebo (2 arms). Primary endpoint: Primary efficacy: agitation symptoms. Started Aug 2024; status: recruiting.
02
Drugs
KNX100
03
Conditions
Dementia
Beyond the preview
Go deeper on ACTRN12624000747527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000747527.